↑ Rising
Health
How a Promising Pancreatic Cancer Drug Loses Its Punch
A new Phase 3 trial launches a dual‑target therapy for RAS‑mutated pancreatic cancer, even as early hopes waver.
Rasonque
4 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Rasonque
This hub groups 4 separate news trends connected to Rasonque, spanning August 26, 2026 through October 4, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 41 article observations and 39 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Newly approved pancreatic cancer drug shows promise in lung cancer
Newly approved pancreatic cancer drug may extend survival for lung cancer patients.
◼ Archived
Business
🔮 fades ✓
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
The FDA's approval of a $480,000-a-year pill for pancreatic cancer has sparked debate over the future of cancer drug pricing.
◼ Archived
Business
🔮 fades ✓
FDA approves landmark pancreatic cancer drug that’s shown to improve survival
A new drug has been approved for pancreatic cancer, but it's not clear who will pay for it.